Serum survivin predicts responses to treatment in active rheumatoid arthritis: a post hoc analysis from the SWEFOT trial

Table 1 Baseline clinical characteristics of patients with early RA enrolled into SWEFOT, divided by survivin status

Variables	Survivin-positive	Survivin-negative	P value
	n = 114	n = 188
Age (years)	56.0 (43.0, 62.25)	57.0 (44.0, 67.0)	0.332
Sex (F)	77 (68 %)	143 (76 %)	0.107
Duration	5.0 (4.0, 8.0)	5.0 (4.0, 8.75)	0.905
RF (+)	91/113 (81 %)	108/187 (58 %)	<0.001
Anti-CCP (+)	71/107 (66 %)	103/183 (56 %)	0.091
Pain-VAS	60.0 (45.75, 72.0)	54.0 (39.0, 71.0)	0.269
PtGA-VAS	60.0 (39.0, 77.0)	58.0 (35.25, 74.0)	0.452
HAQ	1.25 (0.85, 1.75)	1.0 (0.75, 1.5)	0.079
TJC	8.0 (5.0, 13.0)	9.5 (6.0, 14.0)	0.134
SJC	11.0 (6.0, 14.0)	10.0 (7.0, 14.0)	0.692
ESR	35.0 (21.5, 63.0)^a	34.0 (19.25, 50.0)	0.260
CRP	17.0 (9.0, 54.5)^a	18.0 (9.0, 37.0)	0.628
DAS28	5.78 (5.06, 6.35)^a	5.72 (5.02, 6.43)	0.751

^aNumber of patients, n = 113. Serum levels of survivin >0.45 ng/mL indicate survivin-positive patients. Statistics in the groups are presented as medians and interquartile range (IQR). Comparisons between the groups were done by Mann–Whitney U tests for continuous variables, and by Pearson’s χ² tests for frequencies. Anti-CCP, antibodies to cyclic citrullinated peptides; CRP, C-reactive protein; DAS28, 28-joint count disease activity score; ESR, erythrocyte sedimentation rate; F, females; HAQ, Health Assessment Questionnaire; pain-VAS, visual analog scale for pain; PtGA-VAS, patient’s global assessment of disease activity; RA, rheumatoid arthritis; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count

ISSN: 1741-7015